Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553738 | 0.88 | CYP1A2 (0.33) | MAPTKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL18515796 | 0.88 | ALDH1A1 (0.30) | MAPTKDM4EALOX15SMN1; SMN2 | |
| SCHEMBL12464630 | 0.85 | — | — | |
| SCHEMBL29955232 | 0.84 | CA12 (0.38) | SMN1; SMN2 | |
| SCHEMBL22842446 | 0.84 | — | — | |
| SCHEMBL26296846 | 0.82 | MEN1 (0.35) | — | |
| SCHEMBL21861532 | 0.79 | ALDH1A1 (0.41) | ALOX15 | |
| SCHEMBL21698630 | 0.78 | — | — | |
| SCHEMBL6651598 | 0.78 | — | — | |
| SCHEMBL14535211 | 0.78 | TDP1 (0.54) | MAPTKDM4EALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10035970-B2 | Friction-reducing compound, method of producing same, and lubricant composition | BASF SE (DE) | 2018-07-31 | — | — | US | disclosed |
| US-10035970-B2 | Friction-reducing compound, method of producing same, and lubricant composition | BASF SE (DE) | 2018-07-31 | — | — | US | disclosed |
| US-20170321147-A1 | Friction-Reducing Compound, Method of Producing Same, and Lubricant Composition | BASF SE (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20170321147-A1 | Friction-Reducing Compound, Method of Producing Same, and Lubricant Composition | BASF SE (DE) | 2017-11-09 | — | — | US | disclosed |
| US-20160333003-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-17 | — | — | US | disclosed |
| WO-2015109248-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-23 | — | — | WO | disclosed |
| US-8980242-B2 | Aliphatic prodrug linker | ASCENDIS PHARMA GMBH (DK) | 2015-03-17 | — | — | US | disclosed |
| EP-1909845-B1 | N,N-BIS-(2-HYDROXYETHYL) GLYCINE AMIDE AS LINKER IN POLYMER CONJUGATED PRODRUGS | ASCENDIS PHARMA AS (DK) | 2012-08-15 | — | — | EP | disclosed |
| US-20100291021-A1 | ALIPHATIC PRODRUG LINKER | ASCENDIS PHARMA GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| EP-1909845-A2 | N,N-BIS-(2-HYDROXYETHYL) GLYCINE AMIDE AS LINKER IN POLYMER CONJUGATED PRODRUGS | Complex Biosystems GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006136586-A2 | N, N-BIS- (2-HYDROXYETHYL) GLYCINE AMIDE AS LINKER IN POLYMER CONJUGATED PRODRUGS | COMPLEX BIOSYSTEMS GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-0253275-B1 | QUATERNARY AMMONIUM COMPOUNDS AND THEIR USE | Henkel Kommanditgesellschaft auf Aktien (DE) | 1991-03-06 | — | — | EP | disclosed |
| EP-0253275-A1 | Quaternary ammonium compounds and their use | Henkel Kommanditgesellschaft auf Aktien (DE) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291021-A1 | ALIPHATIC PRODRUG LINKER | PAICS, AADAC, TK1 | MAPT 986/4885KDM4E 2936/4885ALOX15 2151/4885 |
| US-20160333003-A1 | READ-THROUGH COMPOUND PRODRUGS SUPPRESSING PREMATURE NONSENSE MUTATIONS | UPF1, NUDT21, RNMT | MAPT 269/4885KDM4E 2100/4885ALOX15 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.